The present invention relates to a terpenoid derivative having an ability to activate the Keap1 / Nrf2 / ARE signaling pathway and having an excellent anti-inflammatory action and cytoprotective action, and contains the terpenoid derivative as an active ingredient, and the posterior eye caused by oxidative stress The present invention relates to a sustained-release pharmaceutical composition effective for treatment and prevention of diseases. A base material and vitreous body containing the terpenoid derivative of the present invention as an active ingredient and capable of being administered to the vitreous body by continuously releasing the terpenoid derivative under physiological conditions and maintaining the pharmacological action for one week or more A locally administered sustained-release pharmaceutical composition for the treatment or prevention of posterior ocular diseases, which has a form that can be administered to the eye.本発明は、Ｋｅａｐ１／Ｎｒｆ２／ＡＲＥシグナル伝達経路の活性化能を有し、抗炎症作用、細胞保護作用に優れるテルペノイド誘導体と、該テルペノイド誘導体を有効成分として含有し、酸化ストレスに起因する後部眼疾患の治療および予防に有効な徐放性医薬組成物に関する。 本発明のテルペノイド誘導体を有効成分として含有し、生理的条件下、該テルペノイド誘導体を持続的に放出することにより、１週間以上、薬理作用を持続し、硝子体に投与可能な基材および硝子体に投与可能な形態を有する、後部眼疾患治療用または予防用の局所投与型徐放性医薬組成物。
